AI assistant
IMAGION BIOSYSTEMS LIMITED — Capital/Financing Update 2022
Apr 12, 2022
65092_rns_2022-04-12_11d89e46-ebd2-4bb4-a303-6cf1800c4cbc.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
IMAGION BIOSYSTEMS LIMITED
(ASX : IBX )
13 April 2022
Issue of unlisted performance options under Equity Incentive Plan
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer advises that it has today lodged an Appendix 3G for the issue of 2,000,000 Unlisted Performance Options.
Following the approval of the Equity Incentive Plan at the Company’s Annual General Meeting held on 22 July 2020, the Board of Directors have approved the issuance of Unlisted Performance Options to new employees of Imagion Biosystems, who are eligible to participate in the Company’s incentive scheme.
The options have an exercise price of $0.058 per share vesting monthly over three years with expiry dates between 30 April 2027 and 31 March 2030.
-ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Company Secretary of Imagion Biosystems Limited
U.S. Media Contact: Australian Media & Investor Relations: Casie Ost Hannah Howlett, WE Communications [email protected] [email protected] +1-619-693-4428 +61 (0) 450648064
Imagion Biosystems Limited ACN 616 305 027 Level 25, 525 Collins Street, Melbourne VIC 3000